A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients.
作者信息
Assy N, Adams P C, Myers P, Simon V, Ghent C N
出版信息
Gut. 2007 Feb;56(2):304-6. doi: 10.1136/gut.2006.107862.
Abstract
摘要
相似文献
1
A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients.
Gut. 2007 Feb;56(2):304-6. doi: 10.1136/gut.2006.107862.
2
Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
Transplantation. 2007 Jun 27;83(12):1571-6. doi: 10.1097/01.tp.0000266678.32250.76.
3
Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection?
Hepatology. 1998 Jun;27(6):1748-9. doi: 10.1002/hep.510270641.
4
A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.
Hepatology. 1997 Oct;26(4):853-7. doi: 10.1002/hep.510260408.
5
Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation.
J Hepatol. 1995 Aug;23(2):119-22. doi: 10.1016/0168-8278(95)80324-6.
6
A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection.
Liver Transpl Surg. 1998 Jul;4(4):276-9. doi: 10.1002/lt.500040412.
7
Evidence that ursodeoxycholic acid prevents steroid-resistant rejection in adult liver transplantation.
Clin Transplant. 1996 Dec;10(6 Pt 2):658-62.
8
Ursodeoxycholic acid after liver transplantation: does conjugation with taurine make the difference?
Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):469-71.
9
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Liver Transpl Surg. 1999 Jul;5(4):269-74. doi: 10.1002/lt.500050419.
10
Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation.
Transpl Int. 1992;5 Suppl 1:S187-9. doi: 10.1007/978-3-642-77423-2_58.
引用本文的文献
1
What makes the kidney so tolerant?
J Clin Invest. 2024 Aug 15;134(16):e183501. doi: 10.1172/JCI183501.
2
Strategies for Deliberate Induction of Immune Tolerance in Liver Transplantation: From Preclinical Models to Clinical Application.
Front Immunol. 2020 Jul 31;11:1615. doi: 10.3389/fimmu.2020.01615. eCollection 2020.
3
Liver organoids: from basic research to therapeutic applications.
Gut. 2019 Dec;68(12):2228-2237. doi: 10.1136/gutjnl-2019-319256. Epub 2019 Jul 12.
4
Why some organ allografts are tolerated better than others: new insights for an old question.
Curr Opin Organ Transplant. 2019 Feb;24(1):49-57. doi: 10.1097/MOT.0000000000000594.
5
Organ-specific differences in achieving tolerance.
Curr Opin Organ Transplant. 2015 Aug;20(4):392-9. doi: 10.1097/MOT.0000000000000206.
6
Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD008852. doi: 10.1002/14651858.CD008852.pub2.
本文引用的文献
1
Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter?
J Hepatol. 2003 May;38(5):629-34. doi: 10.1016/s0168-8278(03)00088-6.
2
Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression.
Transplantation. 2003 Apr 15;75(7):1045-7. doi: 10.1097/01.TP.0000058472.71775.7D.
3
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
J Hepatol. 2001 Jul;35(1):134-46. doi: 10.1016/s0168-8278(01)00092-7.
4
Recurrent autoimmune hepatitis after orthotopic liver transplantation.
Liver Transpl. 2001 Apr;7(4):302-10. doi: 10.1053/jlts.2001.21449.
5
6
Weaning of immunosuppression in long-term liver transplant recipients.
Transplantation. 1995 Jan 27;59(2):212-7. doi: 10.1097/00007890-199501270-00010.
7
Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients.
Lancet. 1990 Jul 7;336(8706):52-3. doi: 10.1016/0140-6736(90)91564-q.
8
Immunomodulatory effects of ursodeoxycholic acid on immune responses.
Hepatology. 1992 Aug;16(2):358-64. doi: 10.1002/hep.1840160213.
9
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes.
Hepatology. 1992 Sep;16(3):719-23. doi: 10.1002/hep.1840160317.
Zotero 插件